Australian clinical-stage biotechnology company Noxopharm (ASX:NOX) has announced the administration of the first SOF-SKN dose in the HERACLES trial. …
Latest Video
New Stories
-
Brandon BioCatalyst welcomes the inclusion of its CUREator in new program
July 16, 2025 - - Australian Biotech -
Cancer Australia launches research program targeting early-onset cancers
July 16, 2025 - - Latest News -
Imugene completes significant placement and launches share purchase plan
July 16, 2025 - - Australian Biotech -
Lumos Diagnostics signs FebriDx US Distribution Agreement with PHASE Scientific
July 16, 2025 - - Australian Biotech -
Noxopharm confirms first patient dosed in SOF-SKN HERACLES trial
July 16, 2025 - - Australian Biotech -
Final days to help build Australia’s longest running life sciences benchmark survey
July 15, 2025 - - Latest News -
New Australian collaboration to build gene and cell therapy production
July 15, 2025 - - Latest News